Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen names new board member
Mr Carbonnel is a consultant and corporate financial advisor. He is also chairman of the board of Thomson, an international multimedia corporation. Previously, Mr Carbonnel was a managing
Mr Carbonnel is a consultant and corporate financial advisor. He is also chairman of the board of Thomson, an international multimedia corporation. Previously, Mr Carbonnel was a managing
Participants include leading biotechnology investors Index Ventures Growth, Abingworth, Dafna Capital Management, and Merlin Nexus, among others. Certain Micromet board members and affiliated entities also participated in the
The primary objective of the Phase I study is to evaluate the safety and tolerability of PG102. The study design includes evaluation of pharmacodynamic and clinical parameters, to
The international Serve-HF study will focus specifically on the impact of treatment of central sleep apnea (CSA) in patients with heart failure. According to the company, up to
Riociguat demonstrated significantly improved exercise capacity in a Phase II study in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) as compared to baseline
The study showed that after 24 weeks, children treated with Xolair suffered 31% fewer clinically significant exacerbations than those receiving placebo or dummy drug (p=0.007). The study therefore
The study showed sustained improvements in lung function for up to four years (p
However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and response rate when Avastin was added to Tarceva compared to
The two companies have been working together since January 2005 to discover and develop novel therapies for schizophrenia and other central nervous system (CNS) diseases. The new agreement
Existing investors participating in the financing included Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP